NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

The North Chicago-based company announced today it entered into an option-to-license agreement with San Diego-based Neomorph to develop novel therapies for cancers and immune diseases. Neomorph ...

Detroit Lions offensive coordinator Ben Johnson is one of the hottest names of the coaching cycle for the second offseason in a row. Last offseason, Johnson received interest from several teams ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a next-generation obesity candidate from ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...

All year, the Chiefs just got by. One narrow victory after another. Through the regular season and the playoffs. Sunday night, the magic was gone. Sunday night, against a formidable opponent with ...